Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Gray Sheet

Executive Summary

TUNA developer raises $16.5 mil. via direct placement with institutional purchasers and private investors of more than 4.3 mil. shares of common stock priced at about $3.84 per share. The firm also issues warrants for purchasers to buy about 1.1 mil. shares of common stock at $5 per share through May 20, 2001. The capital infusion will be used to "fund ongoing operations" and enable management to increase public awareness and gain approval by state governments to reimburse for benign prostatic hyperplasia procedures involving the firm's transurethral needle ablation (TUNA) system. VidaMed, which introduced the 510(k)-cleared TUNA platform in October 1996 ("The Gray Sheet" Oct. 14, 1996, I&W-4), is launching at the American Urology Association meeting the week of May 31 the PROVu TUNA system. Comprised of a reusable handle, disposable cartridge and telescope, PROVu facilitates access to the middle and lateral-prostatic lobes for TUNA treatment. The system was 510(k)-cleared in November, the company says

You may also be interested in...

99 Days Until MDR: Time Is Running Out For Medtech As Risky, Volatile Future Looms

The last year of the run up to the full implementation of the MDR has been characterized by a flurry of new documents and measures, but industry is adamant that medtech is heading for a crisis that will impact industry and patients alike.

BrightGene Bets On Remdesivir Amid Patent Questions

Despite many uncertainties, Suzhou-based BrightGene sees a bet on generic remdesivir worthy of a $700,000 investment.

QUOTED. 17 February 2020. Ralph Ives.

The Chinese government's plan to reduce tariffs it imposed on a slew of US exports is expected to have minimal impact on the overall medtech industry. See what Ralph Ives, AdvaMed's executive VP for global strategy, said about it here.   




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts